title: [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
abstract: Glucocorticoids (GCs) were widely used for the treatment of various disorders. And Osteoporosis is one of the major complications of glucocorticoid therapy. An increased risk of both vertebral and nonvertebral fractures has been reported with dosages of prednisolone or equivalent as low as 2.5-7.5 mg daily. The skeletal effects of glucocorticoids include both direct and indirect actions on bone that result in an early, transient increase in bone resorption accompanied by a decrease in bone formation, which is maintained for the duration of glucocorticoid therapy. Bisphosphonates are the front-line choice for prevention of fracture in glucocorticoid-treated patients and are recommended renewal GIOP guideline from Japan.
authors.affiliation: Initiative for Rheumatology & Osteoporosis, Nagoya Rheumatology Clinic, Japan.
authors.forename: Ikuko
authors.initials: I
authors.lastname: Tanaka
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids